MedTrace Logo

Real-world Effectiveness and Safety of Treatment With DAAs in Patients With CHC(Chronic Hepatitis C)

NCT03887637 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2019-03-25

No results posted yet for this study

Summary

This is a multi-center, open-label clinical study. This study was aimed to assess the real-world effectiveness and safety of treatment with listed DAAs in patients with CHC and cirrhosis in Southern area of China.

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

DAAs

Patients with CHC and cirrhosis who fulfills the indication of antiviral therapy will be administered with DAAs treatment.

Sponsors & Collaborators

  • Third Affiliated Hospital, Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Shuang C Lin, Professor · Third Sun Yat Sen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-30
Primary Completion
2019-08-30
Completion
2019-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03887637 on ClinicalTrials.gov